Is Immix Biopharma Inc halal to invest in?

According to Musaffa's Shariah screening methodology, Immix Biopharma Inc (IMMX) is currently classified as NOT HALAL as of April 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Immix Biopharma Inc a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Immix Biopharma Inc using these criteria to determine its compliance status.

Can Muslims buy shares of Immix Biopharma Inc?

Muslim investors may consider investing in Immix Biopharma Inc if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Immix Biopharma Inc classified as NOT HALAL?

Musaffa determines the Shariah status of Immix Biopharma Inc by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Immix Biopharma Inc updated?

The Shariah compliance status of Immix Biopharma Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Immix Biopharma Inc become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Immix Biopharma Inc?

You can check the latest Shariah compliance status of Immix Biopharma Inc on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

IMMX Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: April 01, 2026

Report Source: 2025 Annual Report

Analyst's Ratings for Immix Biopharma Inc (IMMX)

Based on 8 analysts giving stock ratings to Immix Biopharma Inc in the past 3 months

Strong
SellSellHoldBuyStrong
Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Immix Biopharma Inc. Stock Analysis IMMX

United States Health Care Small Cap Report: 2025 Annual

Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company is headquartered in Los Angeles, California and currently employs 21 full-time employees. The company went IPO on 2021-12-16. The firm is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and select immune-mediated diseases. The firm's lead cell therapy candidate CAR-T NXC-201 (NXC-201), which is being evaluated in its ongoing United States Phase Ib/II NEXICART-2 (NCT06097832) clinical trial. Its lead program, NXC-201 is a next generation CAR-T targeting B-cell maturation antigen. CAR-T cell therapy is a type of immunotherapy that uses the patient’s own immune cells, modified with its proprietary technology. Its N-GENIUS cell engineering platform with EXPAND technology has produced clinical-stage CAR-T NXC-201, targeting B cell maturation antigen, which is autologous CAR-T being developed to treat AL Amyloidosis.

Key Statistics of Immix Biopharma Inc (IMMX)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$9.56$10.08

Today's Open

$10.03

Volume

603.25K

P/E Ratio (TTM)

52 Week Range

$1.87$11.61

Market Cap

506.80M

Avg. Volume

729.58K

Dividend Yield

Financial Metrics & Statements of Immix Biopharma Inc (IMMX)

FAQ's for Immix Biopharma Inc (IMMX)

According to Musaffa’s Shariah screening methodology, Immix Biopharma Inc (IMMX) is currently classified as NOT HALAL as of April 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.